| Ex vivo study of bevacizumab transport through porcine nasal mucosa. | |
| | |
MedLine Citation:
|
PMID: 22120685 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
INTRODUCTION: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder associated with abnormal angiogenesis and disabling epistaxis, for which bevacizumab is reported to be a new therapeutic option. In the present study, bevacizumab transport in porcine nasal mucosa was investigated to determine antibody bioavailability. MATERIAL AND METHODS: Transmucosal absorption of bevacizumab was examined by using nasal mucosa specimens mounted onto static vertical diffusion cells then treated with bevacizumab solution (25mgmL(-1), 500μg) for 2.5h. Bevacizumab concentrations were measured by enzyme-linked immunosorbent assays. Mucosal integrity was examined by histological examination of treated mucosa. RESULTS: Transmucosal transport of bevacizumab followed a Fickian diffusion process (permeability coefficient: [0.63±22]×10(-6)cms(-1); and steady-state flux: 56.4±19.6μgcm(-2)h(-1)). Total recovery of bevacizumab throughout the 2.5h experiment was 83% of the initial dose distributed (i) at the mucosal surface (263±73μg; ∼53%) and (ii) into (95±14μg; ∼19%) and through (56±26μg; ∼11%) the mucosa. There was no evidence of any noticeable histological effects, confirming the harmlessness of nasal bevacizumab delivery. CONCLUSION: In the present study, absorption of bevacizumab into nasal mucosa was demonstrated, providing new fundamentals that are mandatory for further clinical trials in HHT patients. |
| | |
Authors:
|
Géraldine Samson; Alicia Garcia de la Calera; Sophie Dupuis-Girod; Frédéric Faure; Evelyne Decullier; Gilles Paintaud; Céline Vignault; Jean-Yves Scoazec; Christine Pivot; Henri Plauchu; Fabrice Pirot |
Related Documents
:
|
18647845 - Premedication to reduce discomfort during screening mammography. 14741815 - Non-ablative scar revision using a long pulsed frequency doubled nd:yag laser. 9010425 - Treatment of syringomyelia associated with arachnoid scarring caused by arachnoiditis o... 20679835 - Topical silicone gel versus placebo in promoting the maturation of burn scars: a random... 16194725 - School performance in early and continuously treated phenylketonuria. 14964745 - Photorejuvenation with intense pulsed light: results of a multi-center study. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-18 |
Journal Detail:
|
Title: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V Volume: - ISSN: 1873-3441 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9109778 Medline TA: Eur J Pharm Biopharm Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011. Published by Elsevier B.V. |
Affiliation:
|
Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Lyon, France; Université de Lyon, EA 4129 Santé Individu Société, Lyon, France; Université Lyon 1, Lyon, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Interspecies difference in placement of developing teeth and its relationship with cross-sectional g...
Next Document: A pharmacokinetic study of a combination of beta adrenoreceptor antagonists - In the isolated perfus...